Analysis
Digital health funding reached $7.4 billion in the first half of 2026, and the pace hasn't slowed since: Pulse's own tracker shows at least $1.85 billion more across nine disclosed digital-health and health-benefits rounds in just the past 30 days:
- Angle Health -- $600M Series C, SMB health benefits (Sept 18).
- Heidi Health -- $340M Series C at a $900M valuation, AI clinical scribe (Sept 22).
- Solstice Oncology -- $225M Series A launch (Sept 9).
- Rightway Healthcare -- $155M round, pharmacy benefits and care navigation (Sept 9).
- MapLight Therapeutics -- $150M follow-on (Sept 9).
- Forus -- $150M Series C at a $3B valuation (Sept 8).
- Thatch -- $108M Series C at a $1B valuation, health benefits (Sept 15).
- Tandem Health -- $100M Series B, clinical AI (Sept 14).
- Corridor -- $25M seed, SMB health benefits (Sept 21).
“- Angle Health -- $600M Series C, SMB health benefits (Sept 18).”
Health-benefits administration is its own cluster inside that list. Angle Health, Thatch and Corridor are all selling some version of AI-driven benefits administration to small and mid-size employers, a segment increasingly choosing to self-insure rather than buy fully-insured plans -- a structural shift that creates recurring administrative complexity these companies are pricing themselves against.
The category's history matters here: digital health spent much of 2024 and 2025 in a funding drought after the pandemic-era boom cooled, and investors are crediting this rebound to AI-powered clinical and administrative tools finally producing measurable ROI rather than the efficiency promises that drove the earlier, less disciplined wave of checks.
None of this means every name on the list clears the same bar. A $100 million-plus Series B or C is now common enough in digital health that round size alone no longer signals differentiation -- the deals worth watching are the ones where the underlying data or distribution advantage would survive a slower funding environment, not just this one.